Pulmonary hypertension is a chronic life-threatening disease that cripples the lungs and heart.
The only currently approved therapy for PHT is intravenous, complicated by administration difficulties and side effects. Though limited in patient number, the findings are important and relevant considering the magnitude of the clinical and hemodynamic responses which achieved statistical significance. Pulmonary hypertension is a life-threatening condition with a survival rate in untreated patients of only 40 to 55 percent at two years from the onset of symptoms. The study was conducted in six treatment centers, five in the U.S. and one in France. The most common adverse event was headache.